Despite Nature Biotechnology's best efforts on the telephone, fax, pager, and e-mail to quiz the campaigns of the main US presidential candidates-Vice President Al Gore and Republican Governor George W. Bush-about their plans for agbiotech, specifics have not been forthcoming. In fact, hardly anything about the candidates' views on any aspect of biotechnology has been made public from what we can gather.
We do know that neither Gore nor Bush mentions agricultural research among their top priorities in science and technology. As usual, biomedical research takes center stage, with Gore proposing an $18 billion increase in the budget over 10 years and Bush also hinting increases. Both candidates have, however, emphasized the importance of a science-based approach to the regulatory oversight of GM crops; and Bush has been particularly bullish about trade, warning that he will not tolerate EU barriers to the import of new US GM crops. This is fine as far as it goes, but really how far is that? Dwarfing pharmaceutical biotechnology in world capital many fold, the agricultural sector really deserves some more specific pledges rather than the platitudes we've heard so far. With this in mind, we have a few suggestions of our own that Messrs Gore or Bush might like to consider once they're ensconced in the Oval office.
First, food safety and labeling-Let's state once and for all that safety and labeling standards for foods, food ingredients, and feeds should be applied regardless of the techniques used in their production and manufacture. There is widespread expert consensus about this (in fact, genetic engineering may be safer/more precise than conventional breeding), so why is it even discussed anymore? Foods should continue to be assessed on the basis of substantial equivalence, with labeling required only for (GM) foods that differ significantly in composition or nutritional value from their conventional counterparts. Funding should be allocated to promote research that supports the design of more accurate toxicological and allergenicity tests. For example, on p. 1157, Oliver Fiehn and colleagues report the systematic analysis of over 300 compounds in four different strains of Arabidopsis thaliana; systematic and careful phenotypic analyses of this type could allow more rational determination of product composition and assessment of potential risk. A wider public discussion of the risks of processed and organic food and herbal supplements should also be encouraged to provide a context for the risks of GM products (and perhaps dispel the myth that the former are necessarily always more wholesome and safe).
Second, environmental risks-Yes, thousands of acres of GM crops are grown each year in the US without Armageddon, and over 5,000 field trials of GM plants have been safely conducted since 1987 with no apparent ill effects. However, it is still important to acknowledge that our understanding of gene flow in the environment is still far from complete. More genome manipula-
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tions have been carried out in plants than in any other higher organism, yet we still await the first complete plant genome sequence and a deeper understanding of gene integration, silencing, and stability. If there is a potential that transgenic DNA can be released into the environment and passed onto other organisms, such as bacteria or weedy relatives, we should investigate it. We need to focus research on finding alternatives to the introduction of antibiotic resistance genes (e.g., see p. 1172 this issue), on understanding how recombinant DNA persists in the environment, on the mechanisms and dynamics of gene transfer to weedy relatives, and on the importance of selective pressure on recombination events. Strictly controlled field trials must be allowed to proceed without fear/threat of sabotage so that we can establish the nature (if any) of specific environmental risks. Activists who vandalize field trials and/or terrorize farmers should be locked up.
Third, genetic diversity-Collections of plant and animal germ plasm are a vast resource for genetic improvement and identification of useful traits. This is particularly important because only 12 crops now account for 95% of the world's plant food base. A recent survey by the World Bank's Consultative Group on International Agricultural Research suggests it will require $70 million to upgrade present plant collections, and $8 million per year to maintain them. Conventional breeding during domestication of crop species has left untapped many alleles of potential benefit in wild and unadapted germ plasm. We should make funding available to finance these genetic resources in a more sustainable way and to encourage research into untapped traits.
Last but not least, public funding-Six global corporations now dominate agbiotech, an area that was once a hotbed of entrepreneurial activity. While these corporations have continued to appropriate intellectual property and expand funding of R&D, public funding for agbiotech has remained stagnant for the past five years (last year, US funding was around $3.4 billion; during the same period, the top 6 agrochemical companies made around $22 billion). Low public funding presumably reflects political sensitivity to GM research (and more recently downright unpopularity of its products) in the eyes of certain governments. Because it is not clear that monopolies are particularly good at promoting the development of technology and products beneficial to society increased public funding aimed at promoting biotechnology research for the developing world should be a priority.
So that's a start. Let's hope the incumbent president, whoever he is, reads more than cue cards and briefing statements, and perhaps even reads this editorial. Some clear thinking from Washington about the present realities and future possibilities of agricultural biotechnology would be a welcome change indeed.
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